Patent Term Application for REVUFORJ™ (revumenib), Patent No. 10,683,302 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2025-E-0371

Patent Term Application for REVUFORJ™ (revumenib), Patent No. 10,683,302

Documents

Comments

Description

OPEN

Comment Period OpensFeb 4, 2025

Comment Period ClosesApr 28, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; REVUFORJ FR Doc: 2026-03847	Feb 26, 2026	--

CDER

Patent Term Application for REVUFORJ™

Vitae Pharmaceuticals, Inc

Cooley LLP

(revumenib)

Patent No. 10,683,302

OPEN